Figure 1
Reduction in primary and secondary outcomes from baseline to T21 in the Ma-Pi 2 group vs. controls. Primary outcomes - Percentage change in FBG and PPBG from baseline to T21 in the Ma-Pi 2 group vs. control group. The figure represents the results of the bivariate analysis when the Ma-Pi 2 and control groups were compared in the percentage change between T0 and T21 of the efficacy variables (non-adjusted values). Secondary outcomes - Percentage change in HbA1c, lipid panel, BMI, weight, hip circumference and waist circumference from baseline to T21 in the Ma-Pi 2 group vs. control group. The figure represents the results of the bivariate analysis when the Ma-Pi 2 and control groups were compared in the percentage change between T0 and T21 of the efficacy variables (non-adjusted values).